Literature DB >> 19229504

[Drug-induced lupus erythematosus tumidus during treatment with adalimumab].

S Sohl1, R Renner, U Winter, M Bodendorf, U Paasch, J C Simon, R Treudler.   

Abstract

Patients treated with TNF-alpha inhibitors frequently have serum autoantibodies, but only a few develop clinically apparent lupus erythematosus. The TNF-alpha inhibitor adalimumab is a fully humanized antibody and seems to induce autoantibodies less frequently than other drugs of this group. We report on a patient with rheumatoid arthritis, who developed anti-histone antibodies and lupus tumidus after eight months on adalimumab therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19229504     DOI： 10.1007/s00105-008-1699-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  12 in total

1.  Drug-induced lupus erythematosus in a patient treated with adalumimab.

Authors:  Anne P Spillane; Yang Xia; Patrick J Sniezek
Journal:  J Am Acad Dermatol       Date:  2007-05       Impact factor: 11.527

2.  Adalimumab-induced cutaneous lupus.

Authors:  N Sheth; D Greenblatt; S Patel; K Acland
Journal:  Clin Exp Dermatol       Date:  2007-09       Impact factor: 3.470

3.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

4.  Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies.

Authors:  H Bootsma; P E Spronk; E J Hummel; G de Boer; E J ter Borg; P C Limburg; C G Kallenberg
Journal:  Scand J Rheumatol       Date:  1996       Impact factor: 3.641

5.  From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

Authors:  Mark Lebwohl; Jerry Bagel; Joel M Gelfand; Dafna Gladman; Kenneth B Gordon; Sylvia Hsu; Robert E Kalb; Alexa Boer Kimball; Neil J Korman; Gerald G Krueger; Philip Mease; Warwick L Morison; Amy Paller; David M Pariser; Christopher Ritchlin; Bruce Strober; Abby Van Voorhees; Gerald D Weinstein; Melodie Young; Liz Horn
Journal:  J Am Acad Dermatol       Date:  2007-11-05       Impact factor: 11.527

6.  Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.

Authors:  Maurizio Benucci; Gianantonio Saviola; Paola Baiardi; Emanuela Cammelli; Mariangela Manfredi
Journal:  Clin Rheumatol       Date:  2007-10-10       Impact factor: 2.980

Review 7.  Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

Authors:  Michelle F Costa; Nuha R Said; Bernard Zimmermann
Journal:  Semin Arthritis Rheum       Date:  2007-10-30       Impact factor: 5.532

8.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

9.  Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

Authors:  Michel De Bandt; Jean Sibilia; Xavier Le Loët; Sebastian Prouzeau; Bruno Fautrel; Christian Marcelli; Eric Boucquillard; Jean Louis Siame; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2005-03-01       Impact factor: 5.156

10.  Predictors of infusion reactions during infliximab treatment in patients with arthritis.

Authors:  Meliha C Kapetanovic; Lotta Larsson; Lennart Truedsson; Gunnar Sturfelt; Tore Saxne; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156
View more
  3 in total

1.  [Undesired cutaneous adverse drug reactions: What is new?].

Authors:  R Treudler; J C Simon
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 2.  Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents.

Authors:  Camilla Dalle Vedove; Jan C Simon; Giampiero Girolomoni
Journal:  J Dtsch Dermatol Ges       Date:  2012-09-03       Impact factor: 5.584

3.  Lupus erythematosus tumidus: clinical perspectives.

Authors:  Nikolaos Patsinakidis; Ocko Kautz; Bernhard F Gibbs; Ulrike Raap
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.